RE: Interesting article in the FT today13 Apr 2021 12:38
It might well go to 3.5p as a knee-jerk very short-term reaction, but given we will still be a pharma with nearly 5p/share cash, multiple pre-clinical prospects, the breast cancer result under the belt, and the Juvenescence deal, it's not going to stay there for very long. So it will probably settle at around 5.5-6p until they can put out a new 'story' e.g. about Glioma or something else. No worries about discounted placings after that given the c.£13m cash position.
On the other hand if the news is positive as you say this will absolutely rocket from this EV. Even just 25% of SNG's 'rocket' on the day will be +£75m or +27p on the price (50% would be +54p).